Therapeutic resistance and high recurrence rates in GBM have been attributed to a rare population of cancer stem‐like cells (CSCs) (GBM‐derived CSCs—GSCs), which can be prospectively isolated using a number of molecular markers with prominin‐1 (CD133) being among the most commonly used in current practice (Bao et al., 2006; Rich, 2016; Singh et al., 2004). The gene discussed is PROM1; the disease is glioblastoma.